{"schema_version":"secwatch.filing_event.v1","accession":"0000885725-25-000039","form_type":"8-K","ticker":"BSX","cik":"0000885725","company_name":"BOSTON SCIENTIFIC CORP","filed_at":"2025-07-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.586938+00:00","generated_at":"2026-05-18T03:57:29.653490+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Boston Scientific Q2 net sales $5.06B (+22.8% reported); adj. EPS $0.75 beat guidance; raises FY outlook","bullets":["GAAP EPS $0.53 ($797M net income) vs $0.22 a year ago; adjusted EPS $0.75 vs guidance $0.71-0.73.","Q2 organic net sales growth 17.4% (guidance 13-15%); US sales up 30.7% reported.","Cardiovascular segment grew 26.8% reported; MedSurg up 15.7% reported.","FY2025 guidance raised: organic growth 14-15%; adjusted EPS $2.95-2.99 (prior $2.82-2.87).","Closed acquisitions of Intera Oncology and SoniVie; received expanded FDA label for FARAPULSE PFA System."],"urls":{"canonical":"https://secwatch.observer/filing/0000885725-25-000039","json":"https://secwatch.observer/filing/0000885725-25-000039.json","markdown":"https://secwatch.observer/filing/0000885725-25-000039.md","text":"https://secwatch.observer/filing/0000885725-25-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/885725/000088572525000039/0000885725-25-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/885725/000088572525000039/bsx-20250723.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T03:57:29.653490+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}